Johns Hopkins Drug Discovery
82
page-template,page-template-full_width,page-template-full_width-php,page,page-id-82,page-child,parent-pageid-23,bridge-core-3.0.5,qi-blocks-1.0.6,qodef-gutenberg--no-touch,qodef-qi--no-touch,qi-addons-for-elementor-1.5.5,qode-page-transition-enabled,ajax_fade,page_not_loaded,,qode-theme-ver-29.1,qode-theme-bridge,disabled_footer_bottom,wpb-js-composer js-comp-ver-6.9.0,vc_responsive,elementor-default,elementor-kit-3247,x-shortcodes-v3_0_5

Johns Hopkins NIMH Center for Novel Therapeutics of HIV-Associated Cognitive Disorders

The Johns Hopkins NIMH Center for Novel Therapeutics of HIV-associated cognitive Disorders (HAND) is comprised of an interdisciplinary research team who has pooled their talents to study the nature of HIV-associated neurocognitive disorders (HAND). The JHDD serves as the Therapeutic Core at the center and is responsible for translating findings from basic and clinical research into novel therapeutics for HAND. Some of our ongoing collaborative projects that have therapeutic implications in HAND include Intranasal Insulin, Cystine/Glutamate Antiporter, Glutamine Antagonists, Glutaminase, and Neutral Sphingomyelinase 2.